Physician

Deborah W La Scola, MD

According to 2025 Medicare claims, Deborah Scola, MD (NPI: 1558565077) practices urology in the Cape Girardeau, MO-IL market, with the plurality of this provider's patient population coming from Cape Girardeau, MO. This provider's primary affiliated billing organization is CAPE GIRARDEAU UROLOGY ASSOCIATES, INC. (NPI: 1194734582; TIN: 430984708) and primary practice location at 63703-4927. Scola is affiliated with the Mercy Health ACO, LLC (ACO ID: A2616) and Aledade 98 MO MSSP Enhanced (ACO ID: A4998), participating under the MSSP model.

Scola's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 422 traditional Medicare patients, billed 4,707 HCPCS/CPT codes, and received $176,204 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 775 prescription claims across 288 beneficiaries totaling $74,872 in drug costs, led by Myrbetriq (Mirabegron). 2023 DME data shows 13 claims. Open Payments data shows 41 records totaling $852. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $165,321 and ending at $176,204. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $294,279 and ending at $74,872. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $263 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	603	3,142	$165,321
2016	426	3,008	$86,324
2017	342	2,150	$117,583
2018	458	6,005	$125,951
2019	357	2,080	$80,902
2020	215	580	$53,992
2021	283	702	$66,802
2022	245	519	$46,487
2023	297	1,428	$81,263
2024	422	4,707	$176,204

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	514	3,021	$294,279
2016	397	1,459	$153,263
2017	263	837	$103,637
2018	380	1,557	$230,923
2019	414	1,419	$209,641
2020	238	864	$114,480
2021	335	1,371	$172,492
2022	361	1,417	$217,879
2023	185	402	$54,294
2024	288	775	$74,872

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	88	$17,675
2016	11	56	$6,992
2017	N/R	34	$3,631
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	84	$13,932
2022	N/R	32	$10,113
2023	N/R	13	$1,701
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	178	178	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	203	346	$87
99459	Pelvic exam	124	161	$15
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	134	186	$12
81000	Manual urinalysis test with examination using microscope, non-automated	303	555	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Myrbetriq	Mirabegron	59	2,070	$31,190
Gemtesa	Vibegron	47	1,693	$27,264
Methenamine Hippurate	Methenamine Hippurate	48	1,659	$2,876
Trospium Chloride Er	Trospium Chloride	19	570	$2,283
Tamsulosin Hcl	Tamsulosin Hcl	135	6,093	$1,406

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	41	$852	Dendreon Pharmaceuticals LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Deborah W. La Scola, MD?

Tedicare shows public-source Medicare data for Deborah W. La Scola, MD (NPI 1558565077), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Deborah W. La Scola, MD have ACO affiliation data?

Deborah W. La Scola, MD is shown with ACO affiliation data for Mercy Health ACO, LLC (MSSP, ACO ID A2616) and Aledade 98 MO MSSP Enhanced (MSSP, ACO ID A4998).

What billing organization is linked to Deborah W. La Scola, MD?

Deborah W. La Scola, MD is linked to CAPE GIRARDEAU UROLOGY ASSOCIATES, INC. (billing NPI 1194734582) in the available physician profile data.

Does Deborah W. La Scola, MD have Open Payments data?

Deborah W. La Scola, MD has 41 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.